<DOC>
	<DOCNO>NCT00327249</DOCNO>
	<brief_summary>AMP-007 Phase 1/2 study treatment advance , previously treat multiple myeloma . The first phase study design determine safe dose imexon give patient advance , previously-treated multiple myeloma . The Phase 2 part study design provide additional safety data gain understand whether imexon improve outcome patient multiple myeloma</brief_summary>
	<brief_title>Safety Efficacy Study Imexon Treatment Multiple Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Advanced myeloma , measurable disease define protocol . Prior treatment , least 2 prior regimen require . This may include prior treatment investigational product . Able perform activity daily live . Off prior therapy least 24 week depend drug . Blood count blood chemistry near normal range . If female , neither pregnant nursing . Willing use contraceptive prevent pregnancy . No serious illness . No active malignancy . No serious infection . No current drug therapy myeloma except steroid therapy certain circumstance . Biphosphonate therapy permit . Prior radiation permit . Use corticosteroid amyloid disorder , high dose chronic steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>